$ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.SZ)$
Today, a large bullish candlestick once again turned the market focus towards pharmaceutical stocks. I wonder how many people still remember that since the beginning of last year, pharmaceuticals have not been performing better than technology stocks, with most already halved.
$SIHUAN PHARM (00460.HK)$ In the past six months, there has been a nearly 60% pullback, with Wuxi Bio and Fosun Pharma also in a dismal state, pulling back over 50% from their highs. A few days ago, a fan asked me to analyze Wuxi Bio. Honestly, the stock trend doesn't look great, on the verge of breaking down. But I still recommend holding on calmly because the stock quality is there, and its value remains.
Nowadays, most pharmaceutical stocks, like Wuxi Bio, have already returned to their bottom valuations, presenting a good opportunity. What we need to do is wait quietly for the second spring to arrive.
$CARSGEN-B (02171.HK)$
With the outbreak of the COVID-19 pandemic in 2020, items such as masks, vaccines, and COVID-19 tests, among others, especially pharmaceutical-related stocks, have seen a frenzy of soaring prices. Legitimate stocks have doubled, while speculative stocks have skyrocketed tenfold. I won't delve into the speculative stocks here, as I personally don't touch those kinds of stocks much either.
First, let's look at the impact of news. We need to analyze whether it is temporary or sustainable. Temporary bullish news generally only provides short-term speculative opportunities, while sustainable news is different. Obviously, the impact of the pandemic on pharmaceutical stocks has brought about sustainable performance gains.
But why has the pharmaceutical sector emerged...